Point/counterpoint provides food for thought in nuclear medicine
One of the things a good newsmagazine should do is provide contrasting opinions on important issues. It is something we try to achieve with nearly every article we carry.
One of the things a good newsmagazine should do is provide contrasting opinions on important issues. It is something we try to achieve with nearly every article we carry.
On rare occasions, we have the opportunity to present side-by-side contrasting viewpoints on a timely topic. This month is one of those occasions.
Beginning on page 51, you'll find a point/counterpoint presentation on the future of SPECT imaging and whether it will be supplanted by PET.
Dr. Abass Alavi and Dr. Stanley Goldsmith articulate the pro (PET) and con (SPECT) positions. The articles were commissioned by DI news editor C.P. Kaiser.
The debate is an ideal one for the June issue, which traditionally has a nuclear medicine focus and is distributed at the Society of Nuclear Medicine meeting that takes place this month.
Whether you end up agreeing with Alavi that PET is already replacing SPECT in many indications and will soon take over all of them, or with Goldsmith that SPECT will play an important role in nuclear medicine for many years to come, I think you'll find the discussion enlightening from both a clinical and an economic perspective.
I think you'll also find the discussion contains useful information for both nuclear medicine physicians and the radiologists who practice nuclear medicine on a part-time basis.
John C. Hayes is editor of Diagnostic Imaging
What is the Best Use of AI in CT Lung Cancer Screening?
April 18th 2025In comparison to radiologist assessment, the use of AI to pre-screen patients with low-dose CT lung cancer screening provided a 12 percent reduction in mean interpretation time with a slight increase in specificity and a slight decrease in the recall rate, according to new research.
The Reading Room: Racial and Ethnic Minorities, Cancer Screenings, and COVID-19
November 3rd 2020In this podcast episode, Dr. Shalom Kalnicki, from Montefiore and Albert Einstein College of Medicine, discusses the disparities minority patients face with cancer screenings and what can be done to increase access during the pandemic.
Can CT-Based AI Radiomics Enhance Prediction of Recurrence-Free Survival for Non-Metastatic ccRCC?
April 14th 2025In comparison to a model based on clinicopathological risk factors, a CT radiomics-based machine learning model offered greater than a 10 percent higher AUC for predicting five-year recurrence-free survival in patients with non-metastatic clear cell renal cell carcinoma (ccRCC).
Could Lymph Node Distribution Patterns on CT Improve Staging for Colon Cancer?
April 11th 2025For patients with microsatellite instability-high colon cancer, distribution-based clinical lymph node staging (dCN) with computed tomography (CT) offered nearly double the accuracy rate of clinical lymph node staging in a recent study.
